The FDA approved Genentech’s Tecentriq (atezolizumab) and Tecentriq Hybreza as adjuvant treatment for muscle-invasive bladder cancer patients who are circulating tumor DNA (ctDNA)-positive after cystectomy, as determined by Natera’s Signatera CDx MRD test. The decision marks the first FDA approval of a ctDNA MRD-guided therapy and the first authorization of a blood-based MRD assay as a companion diagnostic.